Eisai is seeking reimbursement for its drug LEQEMBI to target Alzheimer's disease in the Canadian market.
1 report, 1 independent
Updated Aug 31
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eisai is seeking reimbursement for its drug LEQEMBI to target Alzheimer's disease in the Canadian market.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Eisai
Japanese pharmaceutical company
Nothing else this week.